Mesenchymal stem cells in ischemic tissue regeneration.

Area of Science:

• Regenerative Medicine
• Stem Cell Therapy
• Ischemic Disease Research

Background:

• Ischemic diseases, including myocardial infarction, stroke, and critical limb ischemia, are leading global causes of mortality.
• Current treatments for ischemic conditions provide incomplete recovery, highlighting the need for novel therapeutic strategies.
• Regenerative medicine, particularly cell-based therapies, presents a promising avenue for treating ischemic disorders.

Purpose of the Study:

• To review the mechanisms of action and therapeutic effects of mesenchymal stem cells (MSCs) in treating ischemic diseases.
• To summarize findings from in vitro experiments, preclinical animal studies, and clinical trials involving MSCs for ischemic conditions.
• To explore strategies for enhancing MSC efficacy in regenerative therapies for ischemic disorders.

Main Methods:

• Comprehensive literature review of in vitro studies on MSC mechanisms.
• Analysis of preclinical animal models investigating MSC therapeutic effects.
• Summary of outcomes from clinical trials utilizing MSCs for ischemic diseases.

Main Results:

• Mesenchymal stem cells (MSCs) exhibit significant secretory and immunomodulatory properties beneficial for ischemic conditions.
• MSC-based therapies have demonstrated potential in reducing inflammation and promoting tissue regeneration in preclinical and clinical settings.
• Therapeutic benefits of MSCs are not consistently satisfactory, indicating a need for optimization.

Conclusions:

• Mesenchymal stem cells (MSCs) represent a viable therapeutic option for ischemic diseases due to their regenerative and immunomodulatory capacities.
• Further research and optimization strategies are required to maximize the clinical benefits of MSCs in regenerative medicine.
• Enhancing MSC function is crucial for improving treatment outcomes in patients suffering from ischemic disorders.